Cantor Fitzgerald sees $META as a major beneficiary of personal AI agents: As AI capabilities continue to advance, we think personal agents have the potential to emerge as the third S-curve in AI. Meta is well positioned to be a leading beneficiary of this theme with a competitive model specifically trained to lead in agentic tasks, a strong harness with a differentiated UX in Muse, and massive compute infrastructure that can help META scale personal agents rapidly into its user base ahead of competition. Believe the unit economics of Muse are being subsidized in the early days, but META has several paths to a profitable freemium model. Analyst: Deepak Mathivanan

CANTOR FITZGERALD JUST MORE THAN DOUBLED ITS BITMINE PRICE TARGET. $30.60 → $63.60 +107.8% Wall Street is starting to reprice BitMine. Something tells me this is only the beginning. $BMNR $ETH

Cantor Fitzgerald Initiates $TEM at Overweight, PT $80 Analyst comments: "TEM is an AI-powered precision medicine data company with most of its upside coming from a single correction: The Street values Data & Applications like a life sciences data vendor, although its growth and margins more closely resemble a platform business. Combined with diversified exposure to biopharma R&D and provider adoption, as well as five under-appreciated growth levers, we believe the risk/reward skews heavily to the upside. Tempus’ D&A segment is mispriced against the wrong peer group, in our view. While Dx trades in-line with its true peer group (6.6x 2028 EV/Revenue, per BLLN, CAI, GH, NTRA, and NEO), D&A does not. The market prices its 26% growth and 76% gross margin off decelerating staffing and hardware-heavy data-vendor peers (IQV, VEEV, TXG, and CERT at 6.1x) instead of the platform businesses whose growth and margin profile it actually matches (PLTR, SNOW, DDOG, and RDDT at 11.7x)." Analyst: Sarah James